Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Dividends Paid - Common (2023)

Gyre Therapeutics (GYRE) has disclosed Dividends Paid - Common for 1 consecutive years, with $1.5 million as the latest value for Q3 2023.

  • On a quarterly basis, Dividends Paid - Common changed N/A to $1.5 million in Q3 2023 year-over-year; TTM through Sep 2023 was $12.8 million, a N/A change, with the full-year FY2022 number at $45.0 million, changed N/A from a year prior.
  • Dividends Paid - Common was $1.5 million for Q3 2023 at Gyre Therapeutics, down from $3.5 million in the prior quarter.
  • In the past five years, Dividends Paid - Common ranged from a high of $7.8 million in Q1 2023 to a low of $1.5 million in Q3 2023.